PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity

• DOI: 10.18632/oncotarget.11273
• Publication Date: 2016-08-13T03:43:07Z
• Authors: Upal Basu-Roy; Eugenia Han; Kirk Rattanakorn; Abhilash Gadi; Narendra Verma; Giulia Maurizi; Preethi H. Gunaratne; Cristian Coarfa; Oran D. Kennedy; Michael J. Garabe...; Claudio Basilico; Alka Mansukhani
• Keywords: 0301 basic medicine; Osteosarcoma; Adipogenesis; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Mice, SCID; Lipid Metabolism; 3. Good health; Mice; 03 medical and health sciences; Dogs; Cell Movement; Mice, Inbred NOD; Cell Line, Tumor; Adipocytes; Neoplastic Stem Cells; Animals; Humans; Hippo Signaling Pathway; Neoplasm Transplantation; Research Paper; Adaptor Proteins, Signal Transducing; Cell Proliferation

Osteosarcoma (OS) is a highly aggressive pediatric bone cancer in which most tumor cells remain immature and fail to differentiate into bone-forming osteoblasts. However, OS cells readily respond to adipogenic stimuli suggesting they retain mesenchymal stem cell-like properties. Here we demonstrate that nuclear receptor PPARγ agonists such as the anti-diabetic, thiazolidinedione (TZD) drugs induce growth arrest and cause adipogenic differentiation in human, mouse and canine OS cells as well as in tumors in mice. Gene expression analysis reveals that TZDs induce lipid metabolism pathways while suppressing targets of the Hippo-YAP pathway, Wnt signaling and cancer-related proliferation pathways. Significantly, TZD action appears to be restricted to the high Sox2 expressing cancer stem cell population and is dependent on PPARγ expression. TZDs also affect growth and cell fate by causing the cytoplasmic sequestration of the transcription factors SOX2 and YAP that are required for tumorigenicity. Finally, we identify a TZD-regulated gene signature based on Wnt/Hippo target genes and PPARγ that predicts patient outcomes. Together, this work highlights a novel connection between PPARγ agonist in inducing adipogenesis and mimicking the tumor suppressive hippo pathway. It also illustrates the potential of drug repurposing for TZD-based differentiation therapy for osteosarcoma.